Predictors of Successful Cardioversion with Vernakalant in Patients with Recent-Onset Atrial Fibrillation.
Research output: Contribution to journal › Article
Vernakalant is a novel atrial-selective antiarrhythmic drug able to convert recent-onset atrial fibrillation (AF) with reportedly low proarrhythmic risk. Successful cardioversion predictors are largely unknown. We sought to evaluate clinical and electrocardiographic predictors of cardioversion of recent-onset AF with vernakalant.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Annals of Noninvasive Electrocardiology|
|State||Published - 2015|
Related research output
Natalia Mochalina, 2017, Lund: Lund University, Faculty of Medicine. 81 p.
Research output: Thesis › Doctoral Thesis (compilation)